Perrigo gets FDA OK on BenzaClin generic

DUBLIN — Perrigo on Tuesday announced that it had received Food and Drug Administration AB therapeutic equivalent rating and approval for its generic of Valeant’s BenzaClin (clindamycin phosphate and benzoyl peroxide) topical gel. Perrigo’s acne treatment gel was concluded to be therapeutically equivalent to Valeant’s.

“This product approval and launch is an important addition to our growing Rx portfolio, through which we continue to provide affordable products to our customers around the world,” Perrigo president, chairman and CEO Joseph Papa said.

The gel had brand sales in the U.S. of $231 million, according to IMS Health data for the 12 months ending July 2015.